Skip to main content

Grafa News and Videos — Page 1517

Latest

Grafa

Genmab’s Rina-S combination shows manageable safety in ovarian cancer trial

Genmab (NASDAQ:GMAB) presented new data at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Monday, demonstrating that its investigational antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), can be safely combined with bevacizumab in patients with advanced ovarian cancer.

Read more: Genmab’s Rina-S combination shows manageable safety in ovarian cancer trial

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift